Pancreatic Cancer Research

ResearcherOsaka International Cancer InstituteActive in the last 2 years

Shigenori Nagata

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5455-6886; OpenAlex author ID A5006168239. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
35
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 12

  1. Clinical significance of non-invasive in vitro drug sensitivity profiling using pancreatic cancer organoids derived from saline flushes collected during routin… Co-author DOI 10.1007/s12094-025-04111-9↗
  2. The effect of neoadjuvant chemoradiation therapy in resectable pancreatic cancer was independent of intratumoral vascularization. Co-author DOI 10.1186/s12876-025-04108-2↗
  3. Mcl-1 expression is a predictive marker of response to gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer. Co-author DOI 10.1038/s41598-024-73020-8↗
  4. Establishment of organoids using residual samples from saline flushes during endoscopic ultrasound-guided fine-needle aspiration in patients with pancreatic ca… Co-author DOI 10.1055/a-1713-3404↗
  5. New Screening System Using Forward-Viewing Radial Endoscopic Ultrasound and Magnetic Resonance Imaging for High-Risk Individuals With Familial History of Pancr… Co-author DOI 10.3389/fmed.2022.928182↗
  6. Predictive Factors for Pancreatic Cancer and Its Early Detection Using Special Pancreatic Ultrasonography in High-Risk Individuals. Co-author DOI 10.3390/cancers13030502↗
  7. Effectiveness of Contrast-Enhanced Ultrasonography for the Characterization of Small and Early Stage Pancreatic Adenocarcinoma. Last author DOI 10.1016/j.ultrasmedbio.2020.04.016↗
  8. A case of stage IA pancreatic ductal adenocarcinoma accompanied with focal pancreatitis demonstrated by contrast-enhanced ultrasonography. Last author DOI 10.1007/s10396-018-0870-5↗
  9. Imaging morphological changes of intraductal papillary mucinous neoplasm of the pancreas was associated with its malignant transformation but not with developm… Co-author DOI 10.1016/j.pan.2015.08.004↗
  10. Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including g… Co-author DOI 10.1007/s00534-012-0514-x↗
  11. Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based che… Co-author DOI 10.1097/sla.0b013e31823d813c↗
  12. Role of Meis1 in mitochondrial gene transcription of pancreatic cancer cells. Co-author DOI 10.1016/j.bbrc.2011.06.066↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenji Ikezawa · 8 shared papers, 2018–2026 · strength 1.26
  2. Kazuyoshi Ohkawa · 8 shared papers, 2018–2026 · strength 1.26
  3. Ryoji Takada · 6 shared papers, 2021–2026 · strength 1.07
  4. Hidenori Takahashi · 7 shared papers, 2012–2026 · strength 0.95
  5. Reiko Ashida · 4 shared papers, 2020–2025 · strength 0.62
  6. Yugo Kai · 3 shared papers, 2022–2026 · strength 0.56
  7. Tatsuya Ioka · 4 shared papers, 2018–2022 · strength 0.46
  8. Makiko Urabe · 2 shared papers, 2024–2026 · strength 0.43
  9. Takuo Yamai · 3 shared papers, 2021–2024 · strength 0.42
  10. Nobuyasu Fukutake · 3 shared papers, 2021–2022 · strength 0.40
  11. Shinichiro Hasegawa · 2 shared papers, 2022–2026 · strength 0.38
  12. Hisataka Ogawa · 2 shared papers, 2022–2026 · strength 0.38
  13. Tomoya Ekawa · 2 shared papers, 2022–2026 · strength 0.38
  14. Hideaki Tahara · 2 shared papers, 2022–2026 · strength 0.38
  15. Junko Fukuda · 3 shared papers, 2018–2021 · strength 0.29
  16. Sachiko Tanaka · 3 shared papers, 2018–2021 · strength 0.29
  17. Kazuhiro Katayama · 3 shared papers, 2018–2021 · strength 0.29
  18. Yuichiro Doki · 2 shared papers, 2012–2025 · strength 0.27
  19. Hidetoshi Eguchi · 2 shared papers, 2012–2025 · strength 0.27
  20. Yoji Kukita · 1 shared paper, 2026 · strength 0.25
  21. Teruki Teshima · 1 shared paper, 2025 · strength 0.24
  22. Hirofumi Akita · 1 shared paper, 2025 · strength 0.24
  23. Tomomi Yasue · 1 shared paper, 2025 · strength 0.24
  24. Ko Watsuji · 1 shared paper, 2024 · strength 0.18
  25. Yusuke Seiki · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.